GSK2636771
- ₹0
- Product name: GSK2636771
- CAS: 1372540-25-4
- MF: C22H22F3N3O3
- MW: 433.42
- EINECS:
- MDL Number:MFCD22417098
- Synonyms:GSK2636771;2-Methyl-1-[[2-Methyl-3-(trifluoroMethyl)phenyl]Methyl]-6-(4-Morpholinyl)-1H-benziMidazole-4-carboxylic acid;GSK2636771/GSK-2636771;GSK 2636771 dihydrochloride;2-Methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic;1H-Benzimidazole-4-carboxylic acid, 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-;2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid GSK2636771;2-METHYL-1-[[2-METHYL-3-(TRIFLUOROMETHYL)PHENYL]METHYL]-6-MORPHOLIN-4-YLBENZIMIDAZOLE-4-CARBOXYLIC ACID
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Melting point :>225°C (dec.)
Boiling point :641.3±55.0 °C(Predicted)
Density :1.38
storage temp. :-20°C Freezer
solubility :DMSO (Slightly), Methanol (Slightly)
pka :-2.70±0.30(Predicted)
form :Solid
color :Pale Yellow
InChI :InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)
InChIKey :XTKLTGBKIDQGQL-UHFFFAOYSA-N
SMILES :C1(C)N(CC2=CC=CC(C(F)(F)F)=C2C)C2=CC(N3CCOCC3)=CC(C(O)=O)=C2N=1
Boiling point :641.3±55.0 °C(Predicted)
Density :1.38
storage temp. :-20°C Freezer
solubility :DMSO (Slightly), Methanol (Slightly)
pka :-2.70±0.30(Predicted)
form :Solid
color :Pale Yellow
InChI :InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)
InChIKey :XTKLTGBKIDQGQL-UHFFFAOYSA-N
SMILES :C1(C)N(CC2=CC=CC(C(F)(F)F)=C2C)C2=CC(N3CCOCC3)=CC(C(O)=O)=C2N=1
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Phosphatidylinositol 3-kinase (PI3K) catalyzes the phosphorylation of phosphatidylinositol at the 3 position to produce the second messengers phosphatidylinositol-3,4-bisphosphate (PtdIns-(3,4)-P2 and PtdIns-(3,4,5)-P3). Class 1 PI3Ks are composed of a p110 catalytic subunit, of which there are four isoforms (p110α, p110β, p110δ, and p100γ), and a p85 regulatory subunit. GSK2636771 is an orally bioavailable inhibitor of PI3K p110β. At 1-10 μM, it decreases cell viability and Akt phosphorylation in p100β-dependent PTEN-deficient PC-3 prostate and BT549 and HCC70 breast cancer cell lines.More related product prices
IPI 145 Pictilisib (GDC-0941) 1217486-61-7 1173900-33-8 Bortezomib 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide GSK-2881078 MethanesulfonaMide, N-[5-[4-[5-[[(2R,6S)-2,6-diMethyl-4-Morpholinyl]Methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-Methoxy-3-pyridinyl]-, rel- GSK2982772 GSK-2256098 GSK 2330672 GSK2879552 CAL-101 GSK 2801 1337531-36-8 1346574-57-9 864082-47-3 GSK 2334470 GSK J4 HCl GSK2837808ARelated product price
- Bortezomib
₹12940 - GSK 2334470
₹16672.2-67099.5 - GSK J4 HCl
₹11677.2-47552.4